Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago,its anti-cancer properties for various malignancies have been under intense investigation.However,the c...Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago,its anti-cancer properties for various malignancies have been under intense investigation.However,the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers.This is due to arsenic＇s rapid clearance by the body＇s immune system before reaching the tumor site.Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success.This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells.Different approaches that have been employed to increase arsenic＇s efficacy,specificity and bioavailability to solid cancer cells were evaluated and compared.The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed.展开更多
目的 探究降钙素原(Procalcitonin,PCT)、C-反应蛋白(C-reactive protein,CRP)、前白蛋白(Proalbumin,PA)水平在实体癌患者合并感染中的临床诊断价值。方法 收集四川省肿瘤医院2017年1月至2018年2月疑似感染并进行了微生物培养、PCT、CR...目的 探究降钙素原(Procalcitonin,PCT)、C-反应蛋白(C-reactive protein,CRP)、前白蛋白(Proalbumin,PA)水平在实体癌患者合并感染中的临床诊断价值。方法 收集四川省肿瘤医院2017年1月至2018年2月疑似感染并进行了微生物培养、PCT、CRP、PA等各临床指标检测的实体癌患者的基本信息并对其进行分组。其中感染组77例,非感染组173例,分别比较两组血清中PCT、CRP、PA的水平差异;探讨PCT、CRP、PA水平与感染组临床病例资料的相关性及其在感染组治疗前后的变化情况;进一步比较感染组内(革兰阴性菌感染、革兰阳性菌感染、真菌感染及混合感染)PCT、CRP、PA水平的差异。结果 PCT、CRP在感染组的水平明显高于非感染组,PA水平则明显低于非感染组,差异有统计学意义( P <0.05);感染组中抗感染治疗前后PCT、CRP水平的变化差异有统计学意义( P <0.05),而PCT、CRP、PA水平与感染组患者临床病例资料无相关性( P >0.05);感染组内真菌感染者CRP水平显著高于其他感染者,差异有统计学意义( P <0.05);PCT、CRP、PA单独检测的ROC曲线下面积(AUC)分别为0.683,0.664,0.627,其中CRP的灵敏度(80.61%)最高,PA的特异度(80.92%)最高,而联合检测的AUC(0.787)高于三者单独检测。结论 PCT、CRP、PA水平对于实体癌患者感染具有一定的诊断和疗效监控价值。展开更多
Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential ...Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential complication in cancer patients. Its management is less established in the medical literature. Materials and Methods: Three cases are presented to illustrate favourable evolution of non-neutropenic biliary-, uro- and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the septic complication. Two of them received subsequent systemic anticancer treatment. Conclusions: Survival benefit offered by the management of cancer-related non-neutropenic sepsis may be comparable to the benefit obtained by systemic anticancer treatments. Cost-effectiveness of sepsis management may be better than that of anticancer treatments.展开更多
文摘Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago,its anti-cancer properties for various malignancies have been under intense investigation.However,the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers.This is due to arsenic＇s rapid clearance by the body＇s immune system before reaching the tumor site.Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success.This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells.Different approaches that have been employed to increase arsenic＇s efficacy,specificity and bioavailability to solid cancer cells were evaluated and compared.The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed.
文摘目的 探究降钙素原(Procalcitonin,PCT)、C-反应蛋白(C-reactive protein,CRP)、前白蛋白(Proalbumin,PA)水平在实体癌患者合并感染中的临床诊断价值。方法 收集四川省肿瘤医院2017年1月至2018年2月疑似感染并进行了微生物培养、PCT、CRP、PA等各临床指标检测的实体癌患者的基本信息并对其进行分组。其中感染组77例,非感染组173例,分别比较两组血清中PCT、CRP、PA的水平差异;探讨PCT、CRP、PA水平与感染组临床病例资料的相关性及其在感染组治疗前后的变化情况;进一步比较感染组内(革兰阴性菌感染、革兰阳性菌感染、真菌感染及混合感染)PCT、CRP、PA水平的差异。结果 PCT、CRP在感染组的水平明显高于非感染组,PA水平则明显低于非感染组,差异有统计学意义( P <0.05);感染组中抗感染治疗前后PCT、CRP水平的变化差异有统计学意义( P <0.05),而PCT、CRP、PA水平与感染组患者临床病例资料无相关性( P >0.05);感染组内真菌感染者CRP水平显著高于其他感染者,差异有统计学意义( P <0.05);PCT、CRP、PA单独检测的ROC曲线下面积(AUC)分别为0.683,0.664,0.627,其中CRP的灵敏度(80.61%)最高,PA的特异度(80.92%)最高,而联合检测的AUC(0.787)高于三者单独检测。结论 PCT、CRP、PA水平对于实体癌患者感染具有一定的诊断和疗效监控价值。
文摘Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential complication in cancer patients. Its management is less established in the medical literature. Materials and Methods: Three cases are presented to illustrate favourable evolution of non-neutropenic biliary-, uro- and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the septic complication. Two of them received subsequent systemic anticancer treatment. Conclusions: Survival benefit offered by the management of cancer-related non-neutropenic sepsis may be comparable to the benefit obtained by systemic anticancer treatments. Cost-effectiveness of sepsis management may be better than that of anticancer treatments.
